canceldeath
Sign in
Nicotinamide riboside
Registry update — unassessed

A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

RCTN=180Minor significance
Share on X
Reporter brief

What this changes

The finding has not established an approved change to our evidence assessment.

Source date: Oct 5, 2026 · Discovered: Oct 5, 2026 · Assessed: — · Research update

What it does not prove

  • No efficacy data are reported in this abstract, so the safety or effectiveness of this combination cannot be assessed from this source.
  • The theoretical rationale linking NAD/sirtuin pathways to ALS progression does not confirm that this specific intervention would work in patients.
  • The study's design and recruitment plan tell us nothing about whether results were positive, negative, or neutral.

Extracted from supplied source material; model confidence is not a measured probability of correctness.

Study details

Design
Rct
Sample size
180
Duration
—
Population
Patients with Amyotrophic Lateral Sclerosis (ALS). Average survival from diagnosis is 3 years.
Primary outcome
Inhibit neurodegeneration in ALS and thereby delay disease development, increase survival and improve quality of life in ALS
Effect size
—
Significance
Not reported
Journal
Haukeland University Hospital
Published
Oct 5, 2026

Sources

Primary source

Recorded source passages

Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.

A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study
Nicotinamide riboside (NR) can increase cells' access to NAD and Pterostilben will stimulate sirtuins.
The investigators want to study whether combination therapy with NR and Pterostilben can inhibit neurodegeneration in ALS and thereby delay disease development, increase survival and improve quality of life in ALS.
strength calculations show that 180 patients are needed to show a rather weak effect
Patients will be recruited in collaboration with hospitals in Helse Vest, AHUS, Drammen, OUS and St. Olavs hospital.

Assessment history

Discussion (0)

One thread per scientific event, no matter how many outlets covered it.

Sign in to join the discussion.

No comments yet

Be the first to weigh in on this evidence.